Peapod Lane Capital LLC acquired a new stake in shares of Aadi Bioscience, Inc. (NASDAQ:AADI – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 442,942 shares of the company’s stock, valued at approximately $1,397,000.
Separately, BML Capital Management LLC acquired a new position in shares of Aadi Bioscience in the 3rd quarter valued at $4,120,000. Institutional investors own 52.08% of the company’s stock.
Aadi Bioscience Stock Performance
AADI opened at $2.68 on Thursday. Aadi Bioscience, Inc. has a 12 month low of $1.21 and a 12 month high of $3.81. The company has a fifty day simple moving average of $2.90 and a 200 day simple moving average of $2.25.
Aadi Bioscience Profile
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
Read More
- Five stocks we like better than Aadi Bioscience
- What is the FTSE 100 index?
- Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Double-Digit Gains Ahead? These 2 Cybersecurity Stocks Look Ready
- Insider Buying Explained: What Investors Need to Know
- Will Falling Bond Yields Send These 2 Small Caps Soaring?
Want to see what other hedge funds are holding AADI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aadi Bioscience, Inc. (NASDAQ:AADI – Free Report).
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
